Session III: Acute Myeloid Leukemia 

Session Chairs: Tapan Kadia, MD and Amir Fathi, MD       

Evolution of Venetoclax Based Combinations | Courtney D. DiNardo, MD, MSCE | MD Anderson Cancer Center, Houston, Texas, USA

Menin Inhibitors – How Do They Compare | Eunice Wang, MD | Roswell Park Cancer Center, Buffalo, New York, USA

FLT3 Combinations in Frontline and Relapse | Jessica K. Altman, MD | Northwestern University, Chicago, Illinois, USA

Debate: Is Low Intensity Therapy Appropriate for Younger Patients With AML - PRO | Amir Fathi, MD | Massachusetts General Hospital, Boston, Massachusetts, USA

Debate: Is Low Intensity Therapy Appropriate for Younger Patients With AML - CON | Christian Récher, MD, PhD | University of Toulouse, Toulouse, France

Older AML: Better Regimens Than HMA-Venetoclax Including HMA-Venetoclax Triplets and Triple-Nucleosides-Venetoclax | Tapan Kadia, MD | MD Anderson Cancer Center, Houston, Texas, USA

Transplant Decisions for AML Based on MRD | R. Coleman Lindsley, MD, PhD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Advancing AML Treatment Through Collaborative Science | Charles Craddock, CBE, FRCP, FRCPath, DPhil, FMedSci | University of Warwick, Coventry, United Kingdom

Oral Abstract | TBD | Speaker | Affiliation